Prognostic Value of Low MicroRNA-34a Expression in Human Gastrointestinal Cancer: a Systematic Review and Meta-analysis

Overview

Journal BMC Cancer

Publisher Biomed Central

Specialty Oncology

Date 2021 Jan 15

PMID 33446130

Citations 4

Authors

Yan-Ling Chen

Xiao-Lin Liu

Ling Li

Affiliations

Soon will be listed here.

Abstract

Background: Mounting evidence shows that microRNA-34a (miR-34a) is involved in cancer prognosis. Therefore, we summarize the predictive role of miR-34a for survival in patients with gastrointestinal cancers (GICs).

Methods: All eligible studies were found by searching PubMed, Web of Science and EMBASE, and survival results were extracted. Then, the hazard ratio (HR) with the corresponding 95% confidence interval (CI) was calculated to evaluate the prognostic role of miR-34a in GICs. The association between miR-34a expression and clinicopathological characteristics was estimated by odds ratios (ORs) and 95% CIs.

Results: A total of 20 studies were included in this meta-analysis. For overall survival (OS), lower miR-34a expression could probably predict poorer outcome in GICs, with a pooled HR of 1.86 (95% CI: 1.52-2.28, P < 0.01). For disease-free survival (DFS), progression-free survival (PFS), and recurrence-free survival (RFS), lower miR-34a expression was related to worse DFS/PFS/RFS with a pooled HR of 1.86 (95% CI: 1.31-2.63, P < 0.01). A significant relation of differentiation/TNM stage/lymphatic metastasis and the expression level of miR-34a was identified.

Conclusion: This meta-analysis revealed that lower miR-34a expression is significantly connected with worse OS and DFS/PFS/RFS in GIC patients. In addition, the miR-34a expression level is relatively lower in patients with lymph node metastasis than in patients without lymph node metastasis, and decreased miR-34a expression levels are linked to poor tumour differentiation and late TNM stage. MiR-34a may become a new factor for the prognosis prediction and progression of GICs.

Citing Articles

The efficacy of Sijunzi on immune function in patients with gastrointestinal cancers after surgery: Integrating systematic review and network pharmacology.

Wu Z, Zhang W, Miao W, Li S, Xie J, Lu W Medicine (Baltimore). 2025; 104(6):e41419.

PMID: 39928794 PMC: 11813061. DOI: 10.1097/MD.0000000000041419.

/MicroRNA-34 axis in cancer and beyond.

Pan W, Chai B, Li L, Lu Z, Ma Z Heliyon. 2023; 9(4):e15155.

PMID: 37095919 PMC: 10121403. DOI: 10.1016/j.heliyon.2023.e15155.

Potential miRNA Use as a Biomarker: From Breast Cancer Diagnosis to Metastasis.

Jordan-Alejandre E, Campos-Parra A, Castro-Lopez D, Silva-Cazares M Cells. 2023; 12(4).

PMID: 36831192 PMC: 9954167. DOI: 10.3390/cells12040525.

Zip Nucleic Acid-Based Genomagnetic Assay for Electrochemical Detection of microRNA-34a.

Erdem A, Eksin E Biosensors (Basel). 2023; 13(1).

PMID: 36671979 PMC: 9856502. DOI: 10.3390/bios13010144.

tRNA-derived fragments in gastric cancer: Biomarkers and functions.

Kohansal M, Ghanbarisad A, Tabrizi R, Daraei A, Kashfi M, Tang H J Cell Mol Med. 2022; 26(18):4768-4780.

PMID: 35957621 PMC: 9465185. DOI: 10.1111/jcmm.17511.

References

Sun T, Xie H, Li Z, Kong L, Gou X, Li D . miR-34a regulates HDAC1 expression to affect the proliferation and apoptosis of hepatocellular carcinoma. Am J Transl Res. 2017; 9(1):103-114. PMC: 5250707. View

Osawa S, Shimada Y, Sekine S, Okumura T, Nagata T, Fukuoka J . MicroRNA profiling of gastric cancer patients from formalin-fixed paraffin-embedded samples. Oncol Lett. 2012; 2(4):613-619. PMC: 3406456. DOI: 10.3892/ol.2011.313. View

Hasakova K, Reis R, Vician M, Zeman M, Herichova I . Expression of miR-34a-5p is up-regulated in human colorectal cancer and correlates with survival and clock gene PER2 expression. PLoS One. 2019; 14(10):e0224396. PMC: 6816564. DOI: 10.1371/journal.pone.0224396. View

Lu T, Rothenberg M . MicroRNA. J Allergy Clin Immunol. 2017; 141(4):1202-1207. PMC: 5889965. DOI: 10.1016/j.jaci.2017.08.034. View

Nalls D, Tang S, Rodova M, Srivastava R, Shankar S . Targeting epigenetic regulation of miR-34a for treatment of pancreatic cancer by inhibition of pancreatic cancer stem cells. PLoS One. 2011; 6(8):e24099. PMC: 3166078. DOI: 10.1371/journal.pone.0024099. View

Jamieson N, Morran D, Morton J, Ali A, Dickson E, Carter C . MicroRNA molecular profiles associated with diagnosis, clinicopathologic criteria, and overall survival in patients with resectable pancreatic ductal adenocarcinoma. Clin Cancer Res. 2011; 18(2):534-45. DOI: 10.1158/1078-0432.CCR-11-0679. View

Lu G, Sun Y, An S, Xin S, Ren X, Zhang D . MicroRNA-34a targets FMNL2 and E2F5 and suppresses the progression of colorectal cancer. Exp Mol Pathol. 2015; 99(1):173-9. DOI: 10.1016/j.yexmp.2015.06.014. View

Lin X, Xu X, Chen Q, Huang C . Clinical significance of microRNA-34a in esophageal squamous cell carcinoma. Genet Mol Res. 2016; 14(4):17684-91. DOI: 10.4238/2015.December.21.41. View

Hu Y, Correa A, Hoque A, Guan B, Ye F, Huang J . Prognostic significance of differentially expressed miRNAs in esophageal cancer. Int J Cancer. 2010; 128(1):132-43. PMC: 2937084. DOI: 10.1002/ijc.25330. View

10.

Wei B, Huang Q, Huang S, Mai W, Zhong X . MicroRNA‑34a attenuates the proliferation, invasion and metastasis of gastric cancer cells via downregulation of MET. Mol Med Rep. 2015; 12(4):5255-61. DOI: 10.3892/mmr.2015.4110. View

11.

Cheng C, Qin Y, Zhi Q, Wang J, Qin C . Knockdown of long non-coding RNA HOTAIR inhibits cisplatin resistance of gastric cancer cells through inhibiting the PI3K/Akt and Wnt/β-catenin signaling pathways by up-regulating miR-34a. Int J Biol Macromol. 2017; 107(Pt B):2620-2629. DOI: 10.1016/j.ijbiomac.2017.10.154. View

12.

Chandrasekaran K, Sathyanarayanan A, Karunagaran D . Downregulation of HMGB1 by miR-34a is sufficient to suppress proliferation, migration and invasion of human cervical and colorectal cancer cells. Tumour Biol. 2016; 37(10):13155-13166. DOI: 10.1007/s13277-016-5261-1. View

13.

Hiyoshi Y, Schetter A, Okayama H, Inamura K, Anami K, Nguyen G . Increased microRNA-34b and -34c predominantly expressed in stromal tissues is associated with poor prognosis in human colon cancer. PLoS One. 2015; 10(4):e0124899. PMC: 4404052. DOI: 10.1371/journal.pone.0124899. View

14.

Sun F, Fu H, Liu Q, Tie Y, Zhu J, Xing R . Downregulation of CCND1 and CDK6 by miR-34a induces cell cycle arrest. FEBS Lett. 2008; 582(10):1564-8. DOI: 10.1016/j.febslet.2008.03.057. View

15.

Yang L, Song X, Zhu J, Li M, Ji Y, Wu F . Tumor suppressor microRNA-34a inhibits cell migration and invasion by targeting MMP-2/MMP-9/FNDC3B in esophageal squamous cell carcinoma. Int J Oncol. 2017; 51(1):378-388. DOI: 10.3892/ijo.2017.4015. View

16.

Stang A . Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses. Eur J Epidemiol. 2010; 25(9):603-5. DOI: 10.1007/s10654-010-9491-z. View

17.

Ohuchida K, Mizumoto K, Kayashima T, Fujita H, Moriyama T, Ohtsuka T . MicroRNA expression as a predictive marker for gemcitabine response after surgical resection of pancreatic cancer. Ann Surg Oncol. 2011; 18(8):2381-7. PMC: 3136688. DOI: 10.1245/s10434-011-1602-x. View

18.

Tierney J, Stewart L, Ghersi D, Burdett S, Sydes M . Practical methods for incorporating summary time-to-event data into meta-analysis. Trials. 2007; 8:16. PMC: 1920534. DOI: 10.1186/1745-6215-8-16. View

19.

Chu J, Li H, Xing Y, Jia J, Sheng J, Yang L . LncRNA MNX1-AS1 promotes progression of esophageal squamous cell carcinoma by regulating miR-34a/SIRT1 axis. Biomed Pharmacother. 2019; 116:109029. DOI: 10.1016/j.biopha.2019.109029. View

20.

Asadi M, Shanehbandi D, Mohammadpour H, Hashemzadeh S, Sepehri B . Expression Level of miR-34a in Tumor Tissue from Patients with Esophageal Squamous Cell Carcinoma. J Gastrointest Cancer. 2018; 50(2):304-307. DOI: 10.1007/s12029-018-0060-0. View